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Background: In response to viral infections, interferons induce the transcription of several hundred genes in
mammalian cells. Specific antiviral functions, however, have only been attributed to a few of them. 90K/LGALS3BP has
been reported to be an interferon-stimulated gene that is upregulated in individuals with cancer or HIV-1 infection.
Results: Here, we show that 90K expression dose-dependently decreased the particle infectivity of HIV-1 progeny. The
lower infectivity of released particles correlated with reduced virion incorporation of mature envelope glycoproteins
gp120 and gp41. Further, proteolytic processing of the gp160 precursor and surface expression of gp120 in the
producer cell were impaired in the presence of 90K expression. In contrast, expression of Gag, Nef and Vpu, and virus
release were not grossly affected by 90K expression. 90K-imposed restriction occurred in the absence of direct
interaction of 90K with HIV-1 Env or entrapment of Env in the ER. The cell-associated, but not the secreted species of
90K, mediated the antiviral effect. A truncated version of human 90K, solely consisting of the two intermediate
domains, displayed a similar antiviral activity as the full-length wildtype 90K, indicating that the N-terminal SRCR-like
domain and the C-terminal domain are dispensable for 90K’s antiviral activity. The murine homolog of 90K, CypCAP
(Cyclophilin C-associated protein), neither modulated particle infectivity of HIV-1 nor lowered the virion incorporation
of mature gp120, suggesting a species-specific mode of action. 90K was expressed at basal levels in TZM-bl cells and
in primary macrophages, and at low levels in CD4+ T-cells and PBMCs. 90K’s susceptibility to IFN-mediated stimulation
of expression was cell type-specific. siRNA-mediated knockdown of 90K in TZM-bl cells and primary macrophages
enhanced the incorporation of Env glycoproteins into progeny virions, boosted the particle infectivity of released
HIV-1, and accelerated HIV-1 spread. Conversely, treatment of HIV-1 infected macrophages with IFN-α induced 90K
expression and lowered the particle infectivity of HIV-1.
Conclusions: Thus, 90K constitutes a novel antiviral factor that reduces the particle infectivity of HIV-1, involving
interference with the maturation and incorporation of HIV-1 Env molecules into virions.
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Human cells are equipped with antiviral proteins that are
capable of disturbing various steps of the replication cycle of
diverse viruses. Notable examples of anti-HIV-1 factors in-
clude members of the apolipoprotein editing complex
(APOBEC) class of cytidine deaminases, which induce lethal
hyper-mutations of the viral genome [1], Tetherin/CD317/
BST2, which causes retention of viral particles on the* Correspondence: christine.goffinet@twincore.de
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distribution, and reproduction in any mediuminfected cell’s surface [2,3], and SAMHD1, that prevents re-
verse transcription in myeloid cells and resting CD4+ T-cells
[4-6]. Expression of these restriction factors is typically inter-
feron (IFN)-responsive [7], and HIV-1 infection results in
their enhanced transcription both ex vivo [8] and in vivo [9].
90K/LGALS3BP, which encodes for a secretory glyco-
protein of 585 amino acids, shares these properties. By
virtue of an IFN-responsive element in the 90K pro-
moter [10], levels of mRNA are enhanced by type I and
type II IFNs in PBMCs [11-13]. Induction of 90K protein
expression by IFN-α has been shown in carcinoma cell
lines [14,15] as well as in vivo following IFN-α adminis-
tration to cancer patients [14,16]. Furthermore, HIV-1ntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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90K in primary CD4+ T-cell cultures [8] as well as in
vivo in HIV-1 infected individuals [9,17-22], although it
remains unclear whether the enhanced 90K levels can be
attributed to HIV-1-infected cells or uninfected by-
stander cells in vivo.
90K, originally identified as a tumor-associated antigen
[14,23,24], is a member of the family of scavenger recep-
tor cysteine-rich (SRCR) domain-containing proteins [25].
It enters the secretory pathway by virtue of its N-terminal
signal peptide and is N-glycosylated in the endoplasmic
reticulum and Golgi complex [26]. Secreted 90K protein is
present in the μg/ml range in several body fluids of
healthy individuals, including blood, semen, urine, tears,
saliva, and breast milk [18,27,28]. Its physiological func-
tions seem to comprise roles in immune response
modulation and cell adhesion. Specifically, secreted
90K promoted NK cell activity, CD8+ T-cell-mediated
lysis activity and cytokine production [11]. Further-
more, secreted 90K induced homotypic cell adhesion
and the formation of multicellular aggregates of tumor
cells [29] by binding to galectin-3/Mac-2.
The inducibility of 90K expression by IFNs and its upreg-
ulated expression in HIV-1 infected individuals prompted
us to investigate whether 90K modulates HIV-1 replication.
In this study, we establish 90K as an antiviral factor that is
associated with the release of poorly infectious virions.
This involved defective maturation of HIV-1 Env during
de novo virus production and reduced incorporation of
Env into progeny virions. The two central protein-binding
domains of 90K were essential and sufficient for its anti-
viral infectivity. 90K protein expression was cell type-
specific, and the degree of IFN-mediated upregulation
of 90K at the protein level differed between macro-
phages and CD4+ T-cells. Depletion of endogenous 90K
in HIV-1 susceptible cells, including TZM-bl cells and pri-
mary macrophages, boosted the particle infectivity of pro-
geny HIV-1, ameliorated Env incorporation into nascent
virions and accelerated the spread of HIV-1. Reduction of
90K expression in PBMCs likewise enhanced HIV-1
spread. Concordantly, IFN-α treatment of primary HIV-1
infected macrophages lowered the particle infectivity of
viral progeny. These data suggest that 90K is an important
contributor of the cellular antiviral defense against HIV-1
infection.
Results
90K expression reduces the particle infectivity of HIV-1
progeny by interfering with the maturation and
incorporation of the viral Env glycoproteins into
progeny virions
In order to investigate whether 90K may affect HIV-1 rep-
lication, 293T cells were cotransfected with a proviral
HIV-1 DNA and decreasing amounts of an expressionplasmid for C-terminally myc-tagged 90K (90K-myc).
Notably, transfection of 293T cells with a 90K-encoding
plasmid resulted in levels of 90K expression that were
clearly higher than those obtained following IFN stimula-
tion (Additional file 1: Figure S1A). Anti-p24 capsid ELISA
analysis showed that 90K-myc expression did not modu-
late the levels of released HIV-1 capsid in the supernatant
(Figure 1A). In contrast, 90K-myc decreased the quantity
of infectious HIV-1 released in the culture supernatant
(Figure 1B). Consequently, the particle infectivity (infectivity
per ng p24CA) was dose-dependently reduced by 90K-myc
expression (Figure 1C).
Anti-HIV-1 p24 capsid Western Blotting of sucrose
cushion-purified supernatants of the producer cells con-
firmed that 90K-myc did not affect levels of released
viral p24 capsid antigen but, in contrast, induced a dose-
dependent decrease in virus-associated gp120 and gp41
Env proteins (Figure 1D).
ELISA analysis of corresponding cell lysates did not
show any detectable effect of 90K expression on cell-asso-
ciated levels of HIV-1 capsid (Figure 1E). Calculation of
HIV-1 capsid release showed that 90K did not interfere
with HIV-1 release (Figure 1G). However, a profound im-
pact of 90K expression on the relative proportion of the
uncleaved gp160 precursor and its cleavage products was
disclosed (Figure 1F). Specifically, expression of 90K-myc
reduced the relative amounts of mature gp120 and gp41,
respectively, whereas it increased the relative levels of
uncleaved gp160 precursor (Figure 1F). Of note, the effect
on gp41 processing was generally lower than on gp120,
possibly due to increased sensitivity of the anti-gp41 anti-
body to cleaved gp41. Thus, 90K expression affected the
proteolytic maturation and virion incorporation of the
HIV-1 Env glycoproteins. Importantly, 90K specifically
inhibited Env biosynthesis, since neither the expression
levels of other viral proteins, including HIV-1 Nef, Gag
and Vpu, nor Gag processing were grossly affected by
90K-myc expression (Figure 1F). Further, expression of
the gfp reporter gene was not affected by 90K-myc, dem-
onstrating that global cellular protein biosynthesis was
not disturbed. 90K-myc expression also reduced the par-
ticle infectivity of R5-tropic HIV-1LAI and HIV-1YU-2, as
well of three transmitted/founder HIV strains (Additional
file 2: Figure S2), indicating that its antiviral activity is not
restricted to viruses of a specific tropism or to laboratory-
adapted viral strains.
90K-myc-mediated inhibition of Env biosynthesis and
of Env virion incorporation occurred in the absence of
any detectable signs of cytoxicity, as assessed by 7-AAD
stain and a luminometric metabolism assay of 90K-myc-
expressing cells (Additional file 3: Figure S3). We next
tested whether expression of 90K-myc in a HIV-1-
susceptible T-cell line might equally result in a reduc-
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Figure 1 Heterologous expression of 90K reduces the particle infectivity of HIV-1 progeny by interfering with the maturation and
incorporation of the viral glycoproteins gp120 and gp41. (A) 293T cells were cotransfected with 1.3 μg pBR.HIV-1 IRES GFP and various
amounts of pcDNA6.90K-myc (1.3, 0.4, 0.15 μg) or empty vector. The total amount of DNA was kept constant (2.6 μg). Supernatants were analyzed for
amounts of released HIV-1 capsid antigen by anti-p24 capsid ELISA and (B) infectious HIV-1 by applying a TZM-bl luciferase assay. (C) Particle
infectivity was defined as infectivity per ng released capsid. Shown are arithmetic means ± S.D. of triplicates. (D) Sucrose cushion-purified virions were
analyzed by immunoblotting. Percentages indicate the relative gp120 and gp41 incorporation, as measured by Infrared imaging-based quantification
of the amount of gp120 and gp41 per p24, respectively. The values of incorporation in absence of 90K expression were set to 100%. (E)
Corresponding cell lysates were analyzed for cell-associated p24 capsid by ELISA. (F) Cell lysates were analyzed by immunoblotting using the
indicated antibodies. Numbers indicate the efficiency of gp120 and gp41 processing, respectively, calculated as the signal ratio of gp120 relative to
(gp120 + gp160), or of gp41 relative to (gp41 + gp160), respectively. (G) Capsid release was calculated as p24 capsid antigen in the supernatant
(p24Sup) to total p24 capsid (p24Cell + p24Sup). The condition without 90K was set to 100%. (H) SupT1 cells were electroporated with pBR.HIV-1 IRES
GFP (10 μg) and pcDNA6.90K-myc or empty vector (10 μg). Three days post transfection, supernatants were harvested and analyzed for particle
infectivity by applying a TZM-bl infectivity assay and an anti-p24 capsid ELISA of the sucrose cushion-purified supernatants. Western Blot analysis of
the producer cells was performed using the indicated antibodies.
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expression vector for 90K-myc or the respective empty
vector control. Sucrose cushion-purified virions from 90K-
myc-expressing producer cells displayed reduced particle
HIV-1 infectivity, compared to empty vector-expressing
cells (Figure 1H). Thus, 90K is also able to reduce the spe-
cific infectivity of progeny HIV-1 in T-cells.Infrared imaging-based protein quantification of West-
ern Blots from multiple experiments corroborated that
90K-myc expression dose-dependently suppressed both
the particle infectivity of released HIV-1, and the incorp-
oration of mature gp120 into virions. A statistical analysis
established a significant correlation of both parameters in
a 90K-dose dependent manner (Figure 2A). Importantly,
Particle infectivity






























































































Figure 2 90K-induced reduction of HIV-1 particle infectivity
correlates with defective gp120 incorporation into progeny,
without influencing virus release. (A) Correlative analysis of
gp120Env content per p24CA and HIV-1 particle infectivity (infectivity
per ng p24) in the supernatant as a function of 90K plasmid amount.
Small symbols represent the values of each individual transfection;
large symbols represent the arithmetic means ± S.E.M. of five-six
individual experiments. The Pearson’s correlation coefficient r and the
corresponding p value were calculated using GraphPad Prism
Software. (B) Correlative analysis of relative released virus and HIV-1
particle infectivity (infectivity per ng p24) in the supernatant as a
function of 90K plasmid amount. Small symbols represent the values
of each individual transfection; large symbols represent the arithmetic
means ± S.E.M. of four individual experiments. The Pearson’s
correlation coefficient r and the corresponding p value were
calculated using GraphPad Prism Software. (C) Relative percentage
of cell-associated gp120Env or gp160 Env versus total detected
anti-gp120 signal as a function of cotransfected 90K plasmid amount.
Values were obtained by Infrared imaging-based quantification of
signals. Small symbols represent the values of each individual
experiment; large symbols represent the arithmetic means ± S.E.M. of
four individual experiments.
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of the signal intensities for cell-associated gp120 and
gp160 confirmed that 90K dose-dependently reduced the
proportion of processed, mature gp120 relative to the
uncleaved gp160 precursor from 63% to 30% (Figure 2C).
Defective maturation of de novo HIV-1 Env may inter-
fere with its subcellular transport towards the plasma
membrane, explaining the paucity of mature HIV-1 Env
in released virions. To investigate whether cell surface
levels of HIV-1 Env are altered in the presence of 90K,
293T cells were cotransfected with a proviral DNA encod-
ing a GFP reporter gene, and 90K-myc or vector and then
subjected to HIV-1 Env surface staining. Surface Env ex-
pression was reduced three-fold by 90K (Figure 3A-B)).
Importantly, 90K did neither interfere with the subcellular
trafficking of another glycoprotein, human CD4, to the
cell surface (Additional file 4: Figure S4A-C), nor did it re-
duce its half-life (Additional file 4: Figure S4D). In con-
trast, HIV-1 Vpu efficiently prevented accumulation of
CD4 at the cell surface and reduced CD4 steady state
levels (Additional file 4: Figure S4C-D).
Our results showed that the antiviral activity of 90K in-
volved interference with the proteolytic maturation of
HIV-1 Env (Figure 1). During its biosynthesis, the proteo-
lytic cleavage of the HIV-1 Env precursor is mediated by
cellular furins and furin-like enzymes residing in the trans-
Golgi compartment of the infected cell [30]. We thus next
analyzed whether 90K may broadly interfere with the pro-
teolytic cleavage of furin-dependent viral and cellular gly-
coproteins. Similarly to provirally expressed HIV-1 Env,
proteolytic processing of CMV promoter driven HIV-1
Env was two-fold less efficient in the presence of 90K




























































































































HIV-1 wt IRES GFPHIV-1 wt IRES GFP
Figure 3 90K-myc reduces cell surface levels of HIV-1 Env and is not a global inhibitor of furin-mediated proteolytic activity. (A) 293T
cells were cotransfected with pBR.HIV-1 IRES GFP and vector or pcDNA6.90K-myc. Two days post transfection, levels of surface HIV-1 gp120 were
assessed by flow cytometry following staining with a human anti-HIV-1 Env antibody. Shown are representative dot plots from one experiment out of
three. Red numbers indicate the MFI in gate P2 (HIV-negative cells) and P3 (HIV-positive cells). (B) Quantitative analysis of relative HIV-1 Env surface
levels in the absence or presence of 90K-myc. Env cell surface levels were calculated by comparing, within the same sample, Env levels on non-GFP-
expressing cells (gate P2) with Env levels on cells with medium-high expression levels (gate P3). The ratio obtained for vector-transfected cells was set
to 100%. Shown is the arithmetic mean ± S.E.M. of three independent experiments. * : p < 0.05 (Student’s T-Test). (C-F) 293T cells were cotransfected
with an expression vector for the indicated furin-dependent glycoproteins (1.3 μg) and vector or pcDNA6.90K-myc (1.3 μg). Two days post
transfection, cells were lysed and proteins were subjected to Western Blotting using the indicated antibodies. Depicted are the efficiencies of
precursor processing, measured by Infrared imaging-based quantification of the respective precursor and the cleavage product.
Lodermeyer et al. Retrovirology 2013, 10:111 Page 5 of 18
http://www.retrovirology.com/content/10/1/111require expression of other HIV-1 proteins. Interestingly,
cleavage of the precursor of Ebola GP, preGP, was also
impaired (3-fold) by 90K (Figure 3D), whereas proteo-
lytic processing of Influenza virus glycoprotein precur-
sor HA0 and of the precursor of cellular glypican-3, two
prototypic furin substrates, was less or not significantly
influenced (Figure 3E-F).
Although sensitivities of the furin substrates to physio-
logic furin concentrations may differ, these results do notprovide evidence for a global interference of 90K with
furin-mediated cleavage of protein precursors and suggest
a specific effect on selected viral glycoproteins. Alterna-
tively, 90K may interfere with HIV-1 Env’s biosynthesis by
trapping it in the ER, thus hampering the accessibility of
the HIV-1 Env precursor to the furin-positive cis-Golgi
compartment. We thus probed a direct interaction of
HIV-1 Env and 90K. Multiple efforts to immunoprecipitate
HIV-1 Env by anti-90K antibodies or vice versa did not
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despite colocolization of HIV-1 Env and 90K-myc
(Additional file 5: Figure S6A-B). In contrast, direct
interaction of HIV-1 Env and CD4 could be shown
(Additional file 6: Figure S5), Deglycosylation tests fur-
ther failed to disclose any 90K-dependent changes in
the subcellular trafficking of HIV-1 Env. Specifically,
PNGase treatment efficiently deglycosylated gp160,
gp41 and 90K (Additional file 7: Figure S7A). Treat-
ment with endoglycosidase H (EndoH), which cleaves
N-linked high-mannose oligosaccharides specifically at-
tached to proteins located in ER/cis-Golgi compart-
ment, including HIV-1 gp160 [31,32], deglycosylated
gp160 with the same efficiency in the absence and pres-
ence of 90K, arguing against 90K retaining a significantly
higher percentage of gp160 in the ER (Additional file 7:
Figure S7B). In contrast, as expected [32], mature gp41
was resistant to EndoH deglycosylation. These results sug-
gest that 90K-imposed antiviral activity does neither in-
volve interference with furin activity, nor require a direct
interaction with HIV-1 Env, nor influence the subcellular
transport of the HIV-1 Env precursor from the ER to the
cis-Golgi.
Conclusively, these results demonstrate that 90K de-
creases the particle infectivity of newly synthesized HIV-
1 particles, probably by interfering with the maturation
and incorporation of the viral glycoproteins via a yet to
be elucidated mechanism.
The cell-associated, but not the secreted species of 90K,
exerts the antiviral activity
By means of its N-terminal signal peptide, the glyco-
protein 90K is routed to the extracellular environment
via the secretory pathway [26,28]. In order to decipher
whether reinternalization of the soluble, secreted species,
or the cell-associated form of 90K is responsible for the
antiviral effect, we inoculated pHIV-1NL4.3-transfected
293T cells with supernatant of 90K-myc-transfected cells
or vector-transfected cells (Figure 4A, left half ). Regard-
less of presence or absence of 90K-myc in the super-
natant, cells produced comparable levels of infectious
HIV-1 (Figure 4A, left half ), whereas cotransfection of
90K-myc potently inhibited HIV-1 infectivity. Consistent
with this observation, preincubation of HIV-1 IRES GFP
virions with 90K-containing supernatants did not affect
their infectivity (Figure 4B).
Additionally, we made use of an ER-resident, secretion-
impaired 90K-myc mutant, 90K(S223P)-myc [26]. Notably,
90K(S223P)-myc expression inhibited HIV-1 production
to a similar extent as wildtype 90K-myc (Figure 4C). We
confirmed that this mutant displays a reduced ability to
be secreted (Figure 4C). Together, these findings favor a
predominant, if not exclusive role of cell-associated 90K
in reducing the levels of HIV-1 infectivity, whereassecreted 90K seems to be dispensable for this restrict-
ing activity.
Endogenous 90K reduces the infectivity of HIV-1
To examine whether endogenous 90K displays anti-HIV-1
activity, we conducted a siRNA-mediated downmodulation
of 90K expression in the HIV-susceptible TZM-bl cell line.
This cell line expressed relatively high endogenous levels
of 90K, although still a factor of 11.5-fold lower than the
level obtained after transfection of 293T cells with the low-
est effective 90K-myc plasmid dose (0.15 μg) (Additional
file 1: Figure S1B). Transfection of TZM-bl cells with a
90K-specific siRNA potently diminished 90K protein ex-
pression as measured by immunofluorescence (Figure 5A),
Western Blotting (Figure 5B) as well as 90K mRNA levels
(Figure 5C), compared to cells transfected with an irrele-
vant control siRNA. Following siRNA-mediated downmo-
dulation of 90K expression, TZM-bl cells were infected
with VSV-G-pseudotyped HIV-1NL4.3. Three days post
infection, culture supernatants were analyzed for p24
capsid antigen release and particle infectivity. Import-
antly, 90K depletion barely affected HIV-1 p24 capsid
release (Figure 5D), but boosted the particle infectivity of
HIV-1 released into the supernatant by 11-fold compared
to control knockdown (Figure 5E), and 90K knockdown
was shown to be efficient at the RNA and protein level
(Figure 5F-G). Western Blot analysis of producer cell
lysates revealed that 90K depletion enhanced the effi-
ciency of gp160 processing, resulting in higher levels
of mature gp120 (Figure 5G), whereas HIV-1 p24 cap-
sid expression was unaltered. Sucrose cushion-purified
virions displayed increased amounts of incorporated ma-
ture gp120 (Figure 5H). Thus, the antiviral potential and
mode of action observed for heterologous 90K (Figures 1
and 2) is recapitulated by endogenously expressed 90K,
despite low expression levels of endogenous 90K.
The two central protein-binding domains of 90K are
required and sufficient for its anti-HIV-1 activity
90K is composed of a N-terminal scavenger receptor cyst-
eine-rich (SRCR) domain, a BTB/POZ domain, an IVR
domain, and a C-terminal part without known homologies
to other protein domains [11]. In order to identify do-
mains which are critical for 90K’s antiviral activity, we
generated a set of truncated 90K variants which each
comprised two domains in their natural order (Figure 6A).
All variants were C-terminally myc-tagged, and encoded
the authentic signal peptide. Following transient transfec-
tion, these variants were expressed at levels similar to
those of wildtype 90K-myc, and they displayed the ex-
pected respective molecular weight (Figure 6B, [33]). Of
note, single domains of 90K were expressed at low to un-
detectable levels, precluding their use for mutational ana-




























































































Figure 4 The cell-associated, but not the secreted species of
90K, exerts the antiviral activity. (A) 293T cells were either
transfected with pBR.HIV-1 NL4.3 IRES GFP and inoculated with
culture supernatant originating from vector-transfected or 90K-
myc-transfected 293T cells (left half), or cotransfected with HIV-1
wt and pcDNA6.90K-myc or empty vector (right half). Two days
post transfection, the amount of infectious HIV-1 in the culture
supernatant was determined. Shown are the arithmetic means ±
S.D. of triplicates originating from one representative experiment
out of two. Supernatants of the cultures from (A) were analyzed
for 90K-myc content. (B) A constant amount of HIV-1 IRES GFP
virions was incubated for 15 min at 37°C with decreasing
amounts of supernatant derived from 293T cells that had been
transfected with empty vector or pcDNA6.90K-myc. TZM-bl were
inoculated with the pretreated virus and analyzed for GFP
expression three days later. Shown are the values of one
representative experiment out of two. An aliquot of the pretreated
inoculum that was given to the TZM-bl cells was analyzed by
Western Blotting. (C) 293T cells were cotransfected with pBR.HIV-1
NL4.3 IRES GFP and indicated expression plasmids. Two days post
transfection, the amount of infectious HIV-1 in the culture
supernatant was determined. Values are normalized to the empty
vector-cotransfected control. Shown are the arithmetic means ± S.E.M.
of three independent experiments. Cell lysates and supernatants
from one representive experiment were analyzed by Western
Blotting. * : p < 0.05 (Student’s T-Test).
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with the infectivity of HIV-1, 293T cells were cotrans-
fected with proviral HIV-1 DNA and the indicated 90K-
myc variants or empty vector. Wildtype 90K-myc reduced
the particle infectivity of HIV-1 virions released in the
culture supernatant, whereas the particle infectivity of
HIV-1 remained largely unchanged in the presence of
90K(1,2)-myc and 90K(3,4)-myc (Figure 6C). However,
90K(2,3)-myc was at least as potent in diminishing
HIV-1 infectivity levels as wildtype 90K-myc, suggest-
ing that the presence of the BTB/POZ and IVR do-
mains of 90K is required and sufficient for 90K’s
antiviral activity. Importantly, 90K(2,3)-myc reduced
the incorporation of HIV-1 gp120 even more potently
than 90K-myc wildtype, whereas viruses produced in
90K(1,2)-myc and 90K(3,4)-myc expressing cells dis-
played normal levels of incorporated HIV-1 gp120
(Figure 6D). Furthermore, the proteolytic cleavage of
gp160 in cells transfected with 90K(2,3)-myc was inef-
ficient, like in 90K-myc wildtype cells, whereas 90K
(1,2)-myc and 90K(3,4)-myc induced only minor changes
in the efficiency of Env processing (Figure 6E).
Conclusively, a region within the two intermediate
protein-binding domains of 90K, the BTB/POZ and the
IVR domain, is required and sufficient for its ability to
interfere with HIV-1 Env maturation and incorporation,
whereas the scavenger receptor cysteine-rich domain
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Figure 5 Endogenous 90K lowers the infectivity of HIV-1. (A) Confocal microscopy of TZM-bl cells immunostained for endogenous 90K and
DAPI. Scale bar: 10 μm. (B) Western Blotting analysis of TZM-bl cells using an anti-90K antibody. Values indicate the relative 90K protein expression,
as measured by Infrared imaging-based quantification. (C) Normalized 90K mRNA levels of the cells shown in (A). (D) Following siRNA transfection,
TZM-bl cells were infected with VSV-G-pseudotyped HIV-1NL4.3 over-night, followed by thorough washing of the cells in order to remove excess virus.
Three days post infection, supernatants were analyzed for released p24 capsid antigen and (E) particle infectivity, defined as infectivity per ng p24.
Bars show the arithmetic means ± S.E.M. of four experiments. (F) 90K knockdown efficiencies of the three experiments shown in (D and E) were
validated by quantitative RT-PCR. Bars show the arithmetic means ± S.E.M. (G) Lysates of infected cells and (H) of sucrose cushion purified viruses
from one representative experiment were analyzed by Western Blotting. Percentages indicate the efficiency of gp120 processing, calculated as the
signal ratio of gp120 relative to (gp120 + gp160), the relative 90K expression, calculated as the signal ratio of 90K relative to MAPK, and the relative
gp120 incorporation, calculated as the amount of gp120 per p24, respectively. **: p < 0.02 (Student’s T-Test).
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Mice encode a 90K homolog, Cyclophilin C-associated
protein (CypCAP), which displays 69% homology onthe amino acid level [34]. Human 90K and murine
CypCAP share the protein organization and the ability
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Figure 6 The two central protein-binding domains of 90K are required and sufficient for the anti-HIV-1 activity of 90K. (A) Schematic of
90K protein organization and of 90K-myc variants. (B) 293T cells were transfected with the indicated constructs, and expression was verified by
Western Blotting using an anti-myc tag antibody. (C) 293T cells were cotransfected with pBR.HIV-1 NL4.3-IRES GFP and the indicated constructs. Two
days post transfection, supernatants were analyzed for particle infectivity, defined as infectivity per ng p24. (D) Sucrose cushion-purified virions of
three experiments were analyzed by immunoblotting. Shown is the relative gp120 incorporation, as measured by Infrared imaging-based
quantification of the amount of gp120 per p24. The signal intensity in absence of 90K expression was set to 100%. (E) Cell lysates were analyzed by
immunoblotting. Shown is the percentage of processed gp120, as measured by Infrared imaging-based quantification of the amount of gp120 per
(gp120 + gp160). The bar diagrams show the arithmetic means ± S.E.M. of six independent experiments. **: p < 0.02 (Student’s T-Test).
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1 replication, including virion assembly and infectivity
[36], hampering the development of an immunocom-
petent small animal model of HIV infection.
We thus tested the ability of mouse CypCAP to reduce
the particle infectivity of progeny HIV-1. Remarkably, the
mouse homolog of 90K failed to act antivirally, whereas
human 90K reduced the particle infectivity of HIV-1
(Additional file 8: Figure S8A). The lack of functional in-
hibition by mouse CypCAP was accompanied by normal
Env glycoprotein incorporation (Additional file 8: Figure
S8B). Although we observed a trend towards slightly de-
creased processing of the gp160 precursor, the difference
was not statistically significant (Additional file 8: Figure
S8C). Thus, these data suggest that the negative mo-
dulations of human 90K on Env maturation and virion in-
corporation are required for its ability to reduce HIV-1
particle infectivity. Furthermore, CypCAP does not seem
to contribute to the inefficiency of late steps of the HIV-1
replication cycle in murine cells.Expression and susceptibility of 90K to IFN stimulation in
primary HIV-1 target cells
90K protein has been reported to be expressed in many tis-
sues and tumor cell lines [11], but whether it is expressed
in CD4+ T-cells and macrophages that represent the
primary HIV-1 target cells in vivo is poorly investigated.
Thus, we examined endogenous 90K mRNA and pro-
tein expression in these cell types. 90K mRNA was
expressed in primary HIV-1 target cells, including acti-
vated PBMCs, CD4+ T-cells and monocyte-derived mac-
rophages (Figure 7A). Notably, IL-2/mitogen stimulation
increased 90K messenger levels in PBMCs and CD4+
T-cells. In line with the documented IFN-responsive-
ness of 90K mRNA expression [14,15], treatment of
primary PBMCs, stimulated CD4+ T-cells, and mono-
cyte-derived macrophages with IFNs resulted in a
marked enrichment of 90K transcripts (Figure 7B).
We next assessed the relative levels of 90K protein ex-
pression in HIV-1 target cells. Western Blot analysis
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Figure 7 Expression and susceptibility to IFN stimulation of 90K in primary HIV-1 target cells. (A) cDNA was prepared from total RNA of the
indicated cell lines and primary cells, and analyzed for relative 90K mRNA expression by TaqMan-based quantitative PCR with RNaseP expression as
a reference. Depicted is the relative level of 90K expression, and values obtained for 293T cells were arbitrarily set to 1. Histograms represent arithmetic
means ± S.E.M. of three independent experiments, except for the data for CD4+ T-cells, which shows arithmetic means of two experiments.
(B) Indicated primary cell cultures were treated with IFN-α (100 U/ml) or IFN-γ (100 U/ml) for 24-48 hours, or left untreated, prior to RNA isolation and
cDNA synthesis. Shown is the fold increase of 90K mRNA level from 2-3 experiments, each performed in duplicates. (C) Western Blot analysis of
indicated cells treated with IFN-α (100 U/ml) or IFN-γ (100 U/ml) for 48 hours, or left untreated. (D) Anti-90K ELISA of cell lysates, following treatment
with IFN-α (100 U/ml) or IFN-γ (100 U/ml) for 48 hours where indicated. (E) Immunofluorescence stain of indicated primary cell cultures. Cells treated
with IFN-α (100 U/ml) or IFN-γ (100 U/ml) for 24-48 hours where indicated or left untreated. Scale bar: 10 μm. (F) Quantification of 90K
immunofluorescence by KNIME image processing plug-in and the mean fluorescence intensity (MFI) signal per cell was determined. The data represent
the arithmetic mean ± S.E.M. of 154 untreated, 259 IFN-α-treated and 147 IFN-γ-treated T-cells and the mean of 85 untreated, 121 IFN-α-treated and 64
IFN-γ-treated macrophages.
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shown) and CD4+ T-cells (Figure 7C), despite detection
of 90K mRNA (Figure 7A), whereas all tested macro-
phages scored positive (Figure 7C). IFN-α, and, to a
lesser extent, IFN-γ treatment enhanced 90K protein
levels in macrophages (Figure 7C). Both IFN-α and
IFN-γ treatment failed to induce 90K protein expres-
sion in CD4+ T-cells to levels detectable by Western
Blotting.
In order to verify the findings on 90K expression ob-
tained by Western Blotting, we made use of a sensitive
commercial anti-90K antigen ELISA for analysis of cell-
associated 90K using lysates of T-cell lines and primary
HIV-1 target cells. This assay revealed that 90K levels
were close to the detection limit in Jurkat T-cells and
CD4+ T-cells, whereas the other T-cell lines scored nega-
tive. In macrophages, screening of macrophages from
multiple donors by anti-90K ELISA confirmed that this
cell type expresses higher 90K protein levels than T-cells.
Immunofluorescence analysis revealed, intuitively intri-
guingly, higher 90K staining intensities in CD4+ T-cells
than macrophages (Figure 7E, middle and bottom panels,
and Figure 7F). However, a direct comparison of the 90K
signals obtained in CD4+ T-cells and macrophages by im-
munofluorescence seems inadequate, since macrophages
and T-cells may greatly differ in their sensitivity to Triton
permeabilization and thus to effective intracellular anti-
body concentrations. The intra-cell type comparison of
IFN-mediated upregulation, however, confirmed that IFN-
α increased 90K expression in macrophages, but not in
CD4+ T-cells. Together, 90K is expressed in macrophages
and, at low levels, in CD4+ T-cells.
Reduction of endogenous 90K expression enhances the
particle infectivity of HIV-1, increases HIV-1 Env content
of progeny virions and accelerates viral spread in primary
HIV-1 target cells
Basal 90K levels in primary macrophages were up to
9-fold lower than levels obtained by transfection of
293T cells with the lowest effective 90K-myc plasmid
dose (0.15 μg) (Additional file 1: Figure S1C). In order toassess the antiviral potential of these low endogenous 90K
expression levels in this primary HIV-1 target cell type, we
infected primary macrophages with VSV-G/HIV-1NL4.3
and subsequently reduced 90K expression by RNAi. Vi-
rions purified from culture supernatants of infected mac-
rophages were examined for their particle infectivity and
for their protein composition. Particle infectivity was en-
hanced by 90K depletion (Figure 8A), and levels of HIV-1
Env were increased in virions produced by 90K-depleted
macrophages compared to virus which originated from
control siRNA-transfected cultures, corroborating 90K’s
ability to induce a paucity of mature Env in virions
(Figure 8A). Analysis of corresponding cell lysates showed
that the efficiency of HIV-1 Env processing was only
mildly increased, suggesting that 90K’s primary mode of
action in macrophages is the inhibition of virion incorpor-
ation of HIV-1 Env, rather than inhibition of Env biosyn-
thesis. We next tested whether 90K depletion influences
HIV-1 spread in primary macrophages. For this purpose,
macrophages from two donors were transfected with a
90K-specific or a control siRNA and subsequently infected
with macrophage-tropic HIV-1Ba-L. Supernatants were an-
alyzed for p24 capsid amounts released in the culture
supernatant as a result of HIV-1 spread. Notably, silencing
of 90K expression was stable and resulted in an enhanced
spread of HIV-1Ba-L (Figure 8B), showing that low en-
dogenous levels of 90K protein can impose a hurdle to
HIV-1 replication.
Given the 90K upregulation following IFN-α stimula-
tion in primary macrophages (Figure 7B-F), we next
tested whether IFN-α treatment translates into a lower
particle infectivity of HIV-1 produced in this primary
cell type. For this purpose, we infected macrophages
with HIV-1Ba-L in the presence or absence of a continu-
ous and moderate dose of IFN-α (100 U/ml). IFN-α
treatment potently reduced the levels of released HIV-1
infectivity (Figure 8C) and, to a lower extent, of released
p24 antigen (Figure 8D), probably involving tetherin-
mediated inhibition of virus release [2,3]. At days 3, 7
and 10 post initiation of IFN-α treatment and HIV-1
infection, the particle infectivity of HIV-1 was severely
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(Figure 8E). Western Blotting of cell lysates demonstrated
potent induction of 90K expression at these time points,
but not at day 1 post initiation of IFN-α treatment and
HIV-1 infection, probably due to too short duration of











































Processed gp120 (%):  55   58 
gp120 Incorporation (%):  100  138
Days Post Infection



















































0 2 4 6










































ls c     90K siRNA
Figure 8 (See legend on next page.)upregulation of multiple genes, these results do not specif-
ically address 90K’s contribution to the IFN-α-mounted
antiviral response. However, they indicate the presence of
IFN-α-induced blocks to particle infectivity and suggest
that 90K may constitute a part of this antiviral defense
response.8
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Figure 8 Depletion of 90K in primary HIV-1 target cells enhances particle infectivity, enhances Env content of HIV-1 particles, and
accelerates HIV-1 spread. (A) VSV-G/HIV-1 NL4.3-infected macrophages were transfected one day post-infection with a 90K-specific or an irrelevant
siRNA. At day 7 post infection, particle infectivity of released HIV-1 was calculated as the ratio of infectivity to p24 capsid antigen. Cell lysates and sucrose
cushion-purified virus were analyzed by Western Blotting. Percentages indicate the relative gp120 incorporation and the efficiency of gp120 processing,
calculated as in Figure 5 (G-H) (B) Macrophages obtained from two donors were siRNA-transfected and subsequently infected with HIV-1Ba-L. One day
post infection, excess virus was removed by thorough washing. Supernatants were subjected to anti-p24 capsid antigen ELISA at indicated time points.
Aliquots of cells were taken for 90K knockdown validation over time by Western Blotting. Shown is 90K expression at day 13 post infection.
(C) Macrophages were infected with HIV-1Ba-L and simultaneously treated with IFN-α (100 U/ml). Supernatants were harvested at the indicated time
points, frozen, and analyzed for released p24 capsid and (D) infectious HIV-1. Shown are arithmetic means of triplicates ± S.D. (E) Using the data from
(C) and (D), the particle infectivity was calculated. Data points indicate arithmetic means of triplicates ± S.D. (F) Cell lysates were subjected to Western
Blotting using indicated antibodies. (G) IL-2/PHA-stimulated PBMCs from two donors were nucleofected with a 90K-specific or an irrelevant siRNA
followed by HIV-1NL4.3 infection over night. Excess virus was removed by thorough washing at indicated time points supernatants were subjected to p24
capsid antigen ELISA. 90K knockdown at the time point of infection was validated by 90K ELISA. * : p < 0.05; **: p < 0.02 (Student’s T-Test).
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in primary PBMCs are sufficient for influencing HIV-1
replication. A two-fold reduction of 90K expression re-
sulted in a modest, but clearly detectable acceleration of
HIV-1 spread in PBMC cultures infected with T-cell
tropic HIV-1NL4.3.
Together, these findings establish that, although low,
endogenous levels of 90K in primary HIV-1 target cells
induce a paucity of mature Env molecules in newly syn-
thesized HIV-1 particles, reduce the infectivity of HIV-1
and impair HIV-1 spread. These findings highlight the
relevance of this antiviral factor in physiologic target cell
types of HIV-1 infection.
Discussion
Although the transcription of many IFN-stimulated genes
is induced upon contact of pathogens with the host cell,
the direct contribution of most of their respective gene
products to the mounting of an antiviral state is poorly
investigated. Here, we propose that 90K is a player of
the intrinsic immune response that may contribute to
HIV-1 restriction.
Two hallmarks of antiviral restriction factors are their
ability to directly and dominantly inhibit specific steps of
the virus replication cycle, and their IFN-induced or IFN-
stimulated expression. These criteria are fulfilled by 90K.
First, heterologous expression and siRNA-mediated deple-
tion studies demonstrated that 90K reduces the particle in-
fectivity of HIV-1, without interfering with particle release,
expression of other viral proteins, or inducing detectable
toxicity. Both heterologous 90K as well as endogenous
90K, expressed in the HIV-1-susceptible TZM-bl cell line
and, most importantly, in primary macrophages and pri-
mary PBMCs, were antiviral. Reduction of particle infec-
tivity by 90K coincided with inefficient proteolytic cleavage
of the gp160Env precursor, reduced cell surface expression
of HIV-1 Env, and limited incorporation of gp120 and
gp41 into progeny virions.
Second, we and others [14-16] clearly demonstrate that
90K expression can be induced or stimulated by IFN-α.Interestingly, 90K protein, but not mRNA, induction seems
to be governed by cell type specific regulation. 293T cells
and macrophages, but not T-cells, were susceptible to IFN-
α-mediated induction and stimulation of 90K protein ex-
pression, respectively. In contrast, T-cells, in addition to
displaying low to undetectable levels of 90K expression,
were refractory to IFN-mediated upregulation of 90K pro-
tein expression. A recent study suggested that T-cells and
macrophages, although equally responsive to IFN-α in
terms of ISG mRNA upregulation, differ in their ability to
mount an antiviral state upon IFN-α-treatment, suggesting
that ISG mRNA induction may not reflect the degree of
protein upregulation in T-cells [37]. Future studies are re-
quired to study in depth the regulation of 90K protein ex-
pression in T-cells.
Physiological levels of 90K in HIV-1-susceptible TZM-
bl cells, primary macrophages and PBMCs were clearly
lower than ectopic antiviral 90K expression levels. Despite
this fact, the limited level of endogenous 90K expression
clearly was able to diminish the particle infectivity of
HIV-1, since siRNA-mediated depletion of endogenous
90K in TZM-bl cells and primary macrophages resulted
in an ameliorated particle infectivity of released virions
and enhanced Env incorporation. In contrast, ectopic 90K
protein seems to display, in relative terms, weak antiviral
activity. Importantly, 90K knockdown resulted in acce-
lerated spread of HIV-1 in primary macrophages and
PBMCs. Interestingly, an IFN-induced loss of particle in-
fectivity of newly synthesized HIV-1 particles has been de-
scribed in PHA/IL-2-stimulated PBMCs [38] and myeloid
U937 cells [39]. In these studies, the reduction of infectiv-
ity was attributed to an aberrant distribution of Env in
intracellular compartments and a marked depletion of en-
velope glycoproteins in released virions. It is plausible that
these effects are, at least partially, caused by 90K.
Since HIV-1 Env and 90K share, by means of their
N-terminal signal peptide, subcellular trafficking through
the secretory pathway, it was tempting to speculate that a
direct or indirect association of these two proteins is re-
quired for 90K’s restricting activity. HIV-1 gp160Env
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and furin-like enzymes located in the trans-Golgi net-
work in order to reach fusogenicity. It is unlikely that
ectopic 90K expression globally interferes with the
furin-mediated cleavage of glycoprotein precursors or
with the subcellular trafficking of glycoproteins to the
cell surface, since neither the processing efficiency of
two other furin substrates, the precursors of FPV HA0
and of cellular glypican-3, nor the subcellular transport
of cellular glycoprotein CD4 to the plasma membrane
were grossly influenced by 90K. Of note, the HA0 pre-
cursor protein studied here is derived from the H7 HA
of Influenza virus and displays a polybasic cleavage site
(KKRKKR) which is highly efficiently cleaved by furin
and may be less sensitive to modest changes of furin
efficacy. HIV-1 Env, in contrast, has been reported to
be a notoriously poor furin substrate [40] and might
require much higher furin levels than the prototypic
furin substrates HA and Glypican-3. Future goals will
consist to probe direct or indirect interaction of furin
and 90K. Notably, however, the proteolytic processing
of the precursor of Ebola GP was severely impaired in
the presence of 90K, suggesting that 90K may reduce
the particle infectivity of Ebola virus.
We next hypothesized that 90K may prevent access of
the unprocessed gp160 precursor to the furin-positive
trans-Golgi compartment by a direct interaction, resulting
in an abolished proteolytic cleavage and, as a consequence,
in a reduced incorporation of mature gp120 into budding
particles. This scenario, however, could not be substan-
tiated by deglycosylation experiments and immunopre-
cipitation assays. These data, however, do not exclude an
indirect association of 90K and HIV-1 Env within a multi-
protein complex. Mutational analysis revealed that the two
central protein-binding domains, BTB/POZ and IVR, are
crucial for 90K’s antiviral activity, whereas the SRCR do-
main and the carboxyterminal domain of 90K were dis-
pensable. Future work will consist to determine the exact
mechanism of 90K-imposed inhibition.
Interestingly, the mouse homolog of 90K, CypCAP,
failed to act antivirally. Cyclophilins catalyze petidyl-prolyl
cis-trans isomerase reactions and assist protein folding
[41]. Whether antiviral human 90K likewise modulates
chaperone activity and whether this is required for exer-
ting the antiviral effect is unknown. Importantly, the in-
activity of the mouse protein was accompanied by
absent alterations of gp120 incorporation and process-
ing, suggesting that these two effects are crucial for hu-
man 90K’s ability to reduce the particle infectivity of
HIV-1. However, 90K’s effect on gp120 processing was
at best mild in primary macrophages, whether virion in-
corporation of Env was clearly increased, suggesting
that inhibition of Env processing and virion incorpor-
ation are not necessarily coupled.In healthy individuals, 90K is present in multiple body
compartments, including blood, semen, urine, tears, sal-
iva, and breast milk [18,27,28]. Despite of its designated
location in the extracellular milieu, we found that not
the secreted species, but rather the cell-associated 90K
exerted the reduction of particle infectivity. However,
that does not exclude that secreted 90K displays antiviral
functions in vivo that may depend on its reported immu-
nostimulatory functions [11]. In line with this possibility,
lack of mother-to-child transmission of HIV-1 correlated
with elevated serum levels of 90K in HIV-1 infected
mothers [42]. Also, elevated levels of 90K in breast milk
were reported to induce protective effects against
acute respiratory infections in breast milk fed children
[27,43]. Furthermore, 90K was recently described as a
ligand of DC-SIGN and may interfere with the captur-
ing of virions that may be required for the trans-infec-
tion of T-cells [44] at sites of primary infection.
A third criterion of many restriction factors is the exi-
stance of virally encoded antagonists against them,
expressed either by HIV-1 or HIV-1 precursors. Work of
our laboratory has provided preliminary evidence for the
presence of an HIV-1 encoded antagonist of human 90K
(unpublished observation), yet the specificity of the ob-
served antagonism is not established and requires sub-
stantial experimental proof. Of note, low density of
glycoprotein molecules on the virus surface is a specific
property of HIV-1, which has been suggested to provide
a selective advantage. Specifically, it has been hypothe-
sized that this feature may enable efficient escape from
antibody-mediated immune response [45]. It is unclear
whether the reduction of infectivity, induced by 90K-
mediated paucity of Env in virions, is outweighed by the
advantage of better immune system escape. Future studies
are required to determine the net antiviral effect of 90K
in vivo, as well as possible viral evasion strategies that
may circumvent 90K-imposed antiviral activity.
Conclusions
This study establishes 90K as an antiviral factor which
impairs the infectivity of HIV-1 progeny, involving de-
fective maturation and incorporation of Env glycopro-
teins. Further investigation and exploitation of its mode
of action may provide a platform for the design of novel
therapeutic antiviral approaches and widen our under-
standing of cell-mediated antiviral defense mechanisms.
Methods
Cells
293T cells, TZM-bl cells and the T-cell lines SupT1, JTag,
PM1, CEM, Jurkat were cultured as recommended by
ATCC. Cultures of primary PBMCs, from random human
donors were generated as previously reported [46]. Taking
of blood samples from humans and cell isolation were
Lodermeyer et al. Retrovirology 2013, 10:111 Page 15 of 18
http://www.retrovirology.com/content/10/1/111conducted with approval of the local ethics committee
(Ethik-Komission der Universität Ulm, approval No. 298/
12). Human blood samples were taken from healthy blood
donors, who provided written informed consent for the
collection of samples and subsequent cell isolation and
analysis. Macrophages were differentiated for 10-15 days
in the presence of 10% human AB serum (Sigma). CD4+
T-cells were isolated from Buffy Coat by negative selec-
tion with the RosetteSep Human CD4+ T Cells Enrich-
ment Cocktail (StemCell Technologies). For the 90K
expression studies, CD4+ T-cells were stimulated with
IL-2/PHA for 2-3 days prior to IFN-α (Roche) or IFN-γ
(Sigma-Aldrich) treatment. 293T cells were transfected
by calcium phosphate DNA precipitation, SupT1 cells
were transfected by electroporation.
Plasmids
pcDNA6 and pcDNA6.90K-myc plasmids were provided
by Ji Hee Lee, South Korea. pIRES2 90K-myc IRES GFP
was generated by PCR amplification of 90K-myc and
insertion into pIRES2-GFP (Clontech) using NheI and
BamHI. The truncated variants of 90K-myc all con-
tained the authentic signal peptide and were generated
by amplification of 90K with the following primers
using HindIII and XbaI and insertion into pcDNA6: fwd





GACCTC and rev CGTCTAGAAATCCGGGGCTTG
TAGGTATCCT (90K(2,3)-myc); fwd CGAAGCTTAT
GACCCCTCCGAGGCTCTTCTGGGTGTGGCTGCTG
GTTGCAGGAACCCAAGGCGTGAACGATGGTCTCC
TCCCCCAGGACCCCTCGTTCCAGATG and rev CCT
CTAGAGTCCACACCTGAGGAGTTGGTCAGG (90K
(3,4)-myc). pcDNA6-mouse CypCAP-myc was generated
by amplification of the mouse cDNA (Sino Biological
Incorportion) using primers carrying HindIII and XbaI re-
striction sites (fwd GCAAGCTTATGGCTCTCCTG and
rev GCTCTAGACACCATGTCAGTG) and ligation of the
amplicon into pcDNA6/myc. Expression constructs for
Glypican-3-HA and H7 Influenza virus HA (derived
from A/chicken/Rostock/8/1934(H7N1)) were provided
by Guido David and Wolfgang Garten, respectively. The
expression plasmid pEbola GP was from Mark Goldsmith.
The CD4 and the HIV-1NL4.3 Env expression plasmid was
from Oliver Keppler. The Vpu-IRES GFP expression con-
struct and the respective control vector have been de-
scribed elsewhere [47].
Viruses
Infectious HIV-1 was generated by calcium phosphate
DNA precipitation of 293T cells with plasmids encodingHIV-1 and harvest of cell-free virion-containing super-
natant. Plasmids encoding NL4.3, LAI, YU-2 were ob-
tained from Oliver Keppler, plasmids encoding transmitter
founder viruses (CHO58, THRO, CHO77) were obtained
from Frank Kirchhoff. The construct pBR.HIV-1 NL4.3-
IRES GFP carries an IRES-EGFP cassette downstream of
the nef ORF [48]. The expression plasmid for VSV-G was
provided by Oliver Keppler. HIV-1 Ba-L was passaged on
PM-1 cells.
HIV-1 infectivity assay
The infectivity of HIV-1 virions was assessed by applying
a standardized TZM-bl based firefly luciferase assay or
beta-galactosidase assay. Readouts were obtained lumi-
nometrically (RLU, relative light units). For calculation
of the particle infectivity, luminometric counts were di-
vided by the content of p24.
Anti-p24 antigen ELISA
Supernatants were analyzed for p24 content (ng/ml) by
applying a home-made anti-p24 antigen ELISA [49].
Cell viability assays
Cells were stained with 7-AAD for detection of dead or un-
healthy cells (BD PharMingen). For measuring metabolic
activity, cell lysates were analyzed using the Cell Titer Glow
assay (Promega). As a positive control for apoptosis induc-
tion or cell death, cells were treated UV-irradiated.
SiRNAs and siRNA-mediated depletion of 90K expression
The following siRNAs were used: control siRNA (Dhar-
macon), 90K-specific siRNA (GAAGCUCUGCCUA-
CAGUUC, from MWG). TZM-bl cells and primary
macrophages were transfected 2-3 times with siRNAs
at the final concentration of 5-15 nM, using RNAiMax
(Invitrogen). PBMCs were transfected twice by Amaxa
nucleofection (Lonza) with final siRNA concentration
of 2.5 μM. Knockdown efficiency was determined by
quantitative RT-PCR of 90K mRNA and RNaseP mRNA
and/or by anti-90K Western Blotting or anti-90K ELISA
(eBioscience).
90K mRNA analysis
Total RNA extraction from untreated or IFN-treated cells
was performed with the Qiagen RNeasy kit (Qiagen),
followed by DNase treatment (Ambion) and cDNA syn-
thesis (NEB, Invitrogen). Quantification of relative 90K
mRNA levels was performed with the Step One Plus
Real Time PCR System (Applied Biosystems) using Taq-




(fluorescent probe). Relative 90K mRNA levels were
Lodermeyer et al. Retrovirology 2013, 10:111 Page 16 of 18
http://www.retrovirology.com/content/10/1/111determined using the ΔΔCt method with human RNa-
seP mRNA (Applied Biosystems) as internal reference.
Each sample was analyzed in duplicates. Data analysis
was performed using Applied Biosystems Step One
Software v2.1.
Confocal immunofluorescence microscopy
Cells grown on coverslips were transfected with Lipofecta-
min2000 (Invitrogen) and fixed with 4% paraformalde-
hyde. They were permeabilized with 0.2% Saponin or 0.1%
TritonX-100, blocked and stained with goat polyclonal
anti-90K (R&D Systems), followed by anti-goat Alexa647,
goat polyclonal anti-myc (novus), followed by anti-goat
Alexa488, or Chessie8 Hybridoma supernatant, followed
by anti-mouse Alexa647. Coverslips were mounted with
Mounting medium containing DAPI (Vectashield) and
analysed with a Zeiss 710 LSM confocal microscope. Im-
ages were recorded and processed with the ZEN (2010)
software. Quantification of 90K expression was performed
by using the open-source KNIME (Kontanz Information
Miner) platform (see http://tech.knime.org/faq#q1_1) in
combination with the KNIME Image Processing 1.0.3 ex-
tension. For segmentation, DAPI stained nuclei were used.
The images were smoothed using a Gaussian Filter
followed by a simple Otsu thresholding. Consecutively,
cells were splitted using a standard cell clump splitter and
additionally filtered by size. After identification of the
cells, the intensity of each pixel was measured, the mean
of intensity for each cell was calculated.
Antibodies
The following antibodies/antisera were used: goat poly-
clonal anti-90K (R&D Systems), mouse anti-myc (pro-
vided by Jens von Einem), goat polycolonal anti-myc
(Novus Biologicals), rabbit anti-MAPK (Santa Cruz),
mouse anti-HIV-1 p24 (Exbio), rabbit anti-HIV-1 gp120
and mouse anti-HIV-1 gp41 (provided by Valerie Bosch),
human 2G12 (NIH), mouse anti-HA (abcam), anti-Ebola
GP (provided by Stephan Becker), anti H7-serum (pro-
vided by Wolfgang Garten), rabbit anti HIV-1 Vpu (pro-
vided by Ulrich Schubert), mouse anti-CD4 (abcam),
anti-CD4-APC (BD).
Immunoblotting
Cells were lysed with M-PER Mammalian Protein Extrac-
tion Reagent (Pierce), and virions were prepared from su-
pernatants and ultracentrifugation through a 20% (w/v)
sucrose cushion. Proteins were run on a 12.5% or 7.5%
SDS-PAGE and transferred onto nitrocellulose. Blocked
membranes were incubated with primary antibodies.
Secondary antibodies conjugated to Alexa680/800 fluores-
cent dyes were used for detection by Odyssey Infrared Im-
aging System (LI-COR Biosciences) and quantification by
Odyssey software.Coimmunoprecipitation
Cells were lysed with 0.5% NP40 lysis buffer and a small
aliquot was used for control of protein expression (Input).
Residual lysate was filled up to final volume of 500 μl with
0.5% NP40 and incubated with antibody for 1 hour at 4°C.
30 μl G-Sepharose Beads (GE-Healthcare) were added
and precipitated 90 minutes at 4°C. Beads were washed
with 0.1% NP40, treated with Western Blot Sample Buffer
and boiled for 5 minutes. Supernatants contained the pre-
cipitated proteins.
Digestion with PNGase or EndoH
Cell lysates were treated with PNGase (NEB BioLabs) and
EndoH (NEB BioLabs) according to instructor’s protocol.
Digestion was performed with 625 Units PNGase for 20 mi-
nutes or with 100 Units EndoH for 5 minutes at 37°C.
Additional files
Additional file 1: Figure S1. Heterologous 90K levels compared to
endogenous 90K levels. (A) 293T cells were cotransfected with various
amounts of pcDNA6.90K-myc (1.3, 0.4, 0.15, 0.05, 0.02 μg), stimulated with
100 Units IFN-α, IFN-γ for 48 h, or left untreated. (B) Western Blot of cell
lysates of 293T cells overexpressing various amounts of 90K-myc (A) and
untreated TZM-bl cells. (C) Western Blot of cell lysates of 293T cells
overexpressing various amounts of 90K-myc (A) and primary macrophages
stimulated with 100 IFN-α, IFN-γ for 48 h, or left untreated. The numbers
depict the relative 90K expression, measured by normalization of the 90K
signal to the MAPK signal obtained by Infrared-imaging based
quantification. The ratio obtained for the lowest antivirally active 90K
plasmid dose (0.15 μg, A), the ratio obtained for TZM-bl cell lysates (B) or
the ratio obtained for untreated macrophages (C) was set to 1, respectively.
Additional file 2: Figure S2. 90K reduces the particle infectivity of
multiple HIV-1 strains. (A) 293T cells were cotransfected with the indicated
proviral plasmids and highest amount of pcDNA6.90K-myc or empty vector.
Supernatants were analyzed for infectious HIV-1 using a luminometric
TZM-based luciferase assay. Shown are the results of one representative
experiment out of three-six. (B) Relative levels of particle infectivity, defined
as HIV-1 infectivity per ng p24 capsid are depicted. (C) Sucrose cushion-
purified virions were analyzed by immunoblotting. Percentages indicate the
relative gp120 incorporation, as measured by Infrared imaging-based
quantification of the amount of gp120 per p24. The signal intensity in
absence of 90K expression was set to 100%. (D) Cell lysates were analyzed
by immunoblotting using the indicated antibodies. Numbers indicate the
efficiency of gp160 processing. * : p < 0.05; **: p < 0.02 (Student’s T-Test).
Additional file 3: Figure S3. 90K-myc expression is not associated with
toxicity or reduced metabolic activity. (A) 293T cells were transfected with
pcDNA6.90K-myc (1.3 μg), empty vector, or UV-irradiated and stained two
days post transfection and one day post UV-irradiation with 7-AAD. Shown
are representative dot plots of one experiment out of two. Numbers
indicate percentage of 7-AAD-positive cells. (B) Quantification of 7-AAD
FACS analysis. (C) Cells were lysed and analysed for metabolic activity by
Cell Titer Glow assay. Shown are the RLU of triplicates obtained from one
representative experiment out of two.
Additional file 4: Figure S4. 90K does not reduce the cell surface
levels of CD4. (A) 293T cells were cotransfected with pcDNA.CD4 and
pIRES2EGFP.90K-myc or empty vector, Cells were stained with APC-
conjugated anti-CD4 and analyzed by flow cytometry. Shown are
representative dot plots of one experiment out of three. (B) 293T cells
were cotransfected with pcDNA.CD4 and pVpu-IRES GFP or empty vector
and processed like in (A). (C) CD4 cell surface levels were calculated by
comparing, within the same sample, CD4 levels on non-GFP-expressing
cells (gate P2) with CD4 levels on cells with medium-high GFP expression
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(D) An aliquot of the cells shown in (A) and (B) were lyzed and analyzed
by Western Blotting using the indicated antibodies.
Additional file 5: Figure S5. 90K and Env colocalize to a high extent. (A)
293T cells were cotransfected with pcDNA6.90K-myc and an HIV-1 Env
expression plasmid, and stained for 90K-myc (green) and Env (red).
Scale bar: 10 μm. (B) The classic colocalization coefficient was calculated
for the colocalization of 90K protein with Env protein or vice versa using
ZEN2010 software. The data represent the arithmetic mean ± S.D. of 105
analyzed cells.
Additional file 6: Figure S6. No evidence for a direct interaction of 90K
and HIV-1 Env. (A-C) 293T cells were cotransfected with pcDNA6,
pcDNA6.90K-myc, an HIV-1 Env expression plasmid, pcDNA.CD4 or a
combination out of these. (A) 90K, CD4 and bound proteins were
precipitated from cell lysates by an anti-90K or anti-CD4 antibody,
respectively. (B) 90K, CD4 and bound proteins were precipitated from cell
lysates by an anti-myc or anti-CD4 antibody, respectively. (C) Env and
bound proteins were precipitated from cell lysates by an anti-gp120
antibody. For each experimental set up, an aliquot of whole cell lysate for
expression control (Input) and the precipitated proteins were analyzed by
Immunoblot with indicated antibodies.
Additional file 7: Figure S7. 90K does not retain Env in the ER. (A-B)
293T cells were cotransfected with pBR.HIV-1 IRES GFP and vector or
pcDNA6.90K-myc. (A) Cell lysates were treated with PNGase. (B) Cell lysates
were treated with EndoH. Deglycosylated and control proteins were
analyzed by Western Blot. Numbers indicate the efficiency of gp41
processing, calculated as the signal ratio of gp41 relative to (gp41 + gp160),
or the percentage of deglycosylated gp160 to the total gp160 signal.
Additional file 8: Figure S8. Species specificity of 90K-imposed antiviral
activity. (A) 293T cells were cotransfected with pBR.HIV-1 NL4.3-IRES GFP
and 1.3 μg of the indicated expression constructs or empty vector. Two
days post transfection, supernatants were analyzed for particle infectivity,
defined as infectivity per ng p24. Cell lysates were analyzed by
immunoblotting. (B) Sucrose cushion-purified virions were analyzed by
immunoblotting. Shown is the relative gp120 incorporation, as measured
by Infrared imaging-based quantification of the amount of gp120 per
p24. The signal intensity in absence of 90K expression was set to 100%.
(C) Cell lysates were analyzed by immunoblotting. Shown is the
percentage of gp120, as measured by Infrared imaging-based
quantification of the amount of gp120 per (gp120 + gp160). Bar diagrams
show the arithmetic means ± S.E.M. of 3-4 independent experiments. The
Western Blot shown is representative for one of the experiments
included in the calculation. **: p < 0.02; n.s. : > 0.05 (Student’s T-Test).
Abbreviations
A.U: Arbitrary units; HIV: Human immunodeficiency virus; IFN: Interferon;
LGALS3BP: Lectin galactoside-binding soluble 3 binding protein; MFI: Mean
fluorescence intensity; RLU: Relative light units.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VL and CG conceptualized and designed the study; VL, KS, NS, CK, CMS, TW,
DK, CG performed the study; TW and CD performed the
immunofluorescence-based quantification of 90K expression; VL, KS, CK, CMS,
CG analyzed data; VL and CG wrote the paper. JM and FK provided reagents.
All the authors reviewed the manuscript and approved the final version.
Acknowledgments
We thank Sebastian Bolduan, Valerie Bosch, Guido David, Giada Frascaroli,
Wolfgang Garten, Mark Goldsmith, Beatrice Hahn, Stefano Iacobelli, Oliver
Keppler, Ji Hee Lee, Xuehua Li, Barbara Müller, Ulrich Schubert, and Jens von
Einem for the kind gift of reagents. We are grateful to Daniel Sauter and
David Palesch for helpful comments on the manuscript. This work was
supported by the Leibniz Award of the German Research Council (DFG) to
Frank Kirchhoff, a PhD Fellowship of Baden-Württemberg (LGFG Stipend) to
VL, by a Margarete von Wrangell Habilitation Fellowship to CG and by a DFG
Research Grant (GO2153/2-1) to CG.Author details
1Institute of Molecular Virology, Ulm University Medical Center, Ulm, Germany.
2Nycomed Chair of Bioinformatics and Information Mining, University of
Konstanz, Konstanz, Germany. 3Doerenkamp-Zbinden Department of in vitro
Toxicology and Biomedicine, University of Konstanz, Konstanz, Germany.
4TWINCORE, Institute of Experimental Virology, Feodor-Lynen-Strasse 7, 30625
Hannover, Germany.
Received: 16 April 2013 Accepted: 14 October 2013
Published: 24 October 2013References
1. Sheehy AM, Gaddis NC, Choi JD, Malim MH: Isolation of a human gene
that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
Nature 2002, 418(6898):646–650.
2. Neil SJ, Zang T, Bieniasz PD: Tetherin inhibits retrovirus release and is
antagonized by HIV-1 Vpu. Nature 2008, 451(7177):425–430.
3. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, Johnson MC,
Stephens EB, Guatelli J: The interferon-induced protein BST-2 restricts
HIV-1 release and is downregulated from the cell surface by the viral
Vpu protein. Cell Host Microbe 2008, 3(4):245–252.
4. Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S,
Florens L, Washburn MP, Skowronski J: Vpx relieves inhibition of HIV-1
infection of macrophages mediated by the SAMHD1 protein.
Nature 2011, 474(7353):658–661.
5. Laguette N, Bregnard C, Benichou S, Basmaciogullari S: Human
immunodeficiency virus (HIV) type-1, HIV-2 and simian immunodeficiency
virus Nef proteins. Mol Aspects Med 2010, 31(5):418–433.
6. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M,
Schenkova K, Ambiel I, Wabnitz G, Gramberg T, et al: SAMHD1 restricts HIV-
1 infection in resting CD4(+) T cells. Nat Med 2012, 18(11):1682–1687.
7. Malim MH, Bieniasz PD: HIV restriction factors and mechanisms of
evasion. Cold Spring Harb Perspect Med 2012, 2(5):a006940.
8. Audige A, Urosevic M, Schlaepfer E, Walker R, Powell D, Hallenberger S, Joller H,
Simon HU, Dummer R, Speck RF: Anti-HIV state but not apoptosis depends on
IFN signature in CD4+ T cells. J Immunol 2006, 177(9):6227–6237.
9. Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV,
Ge D, Gunthard HF, Goldstein DB, et al: Genome-wide mRNA expression
correlates of viral control in CD4+ T-cells from HIV-1-infected individuals.
PLoS Pathog 2010, 6(2):e1000781.
10. Brakebusch C, Sures I, Jallal B, Mossie K, Fusco O, Iacobelli S, Ullrich A:
Isolation and functional characterization of the human 90K promoter.
Genomics 1999, 57(2):268–278.
11. Ullrich A, Sures I, D’Egidio M, Jallal B, Powell TJ, Herbst R, Dreps A,
Azam M, Rubinstein M, Natoli C, et al: The secreted tumor-associated
antigen 90K is a potent immune stimulator. J Biol Chem 1994,
269(28):18401–18407.
12. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald
MR, Rice CM: Interferons alpha and lambda inhibit hepatitis C virus
replication with distinct signal transduction and gene regulation
kinetics. Gastroenterology 2006, 131(6):1887–1898.
13. Waddell SJ, Popper SJ, Rubins KH, Griffiths MJ, Brown PO, Levin M, Relman
DA: Dissecting interferon-induced transcriptional programs in human
peripheral blood cells. PLoS One 2010, 5(3):e9753.
14. Iacobelli S, Scambia G, Natoli C, Panici PB, Baiocchi G, Perrone L, Mancuso S:
Recombinant human leukocyte interferon-alpha 2b stimulates the
synthesis and release of a 90K tumor-associated antigen in human
breast cancer cells. Int J Cancer 1988, 42(2):182–184.
15. Marth C, Dreps A, Natoli C, Zeimet AG, Lang T, Widschwendter M,
Daxenbichler G, Ullrich A, Iacobelli S: Effects of type-I and -II interferons on
90K antigen expression in ovarian carcinoma cells. Int J Cancer 1994,
59(6):808–813.
16. Natoli C, Garufi C, Tinari N, D’Egidio M, Lesti G, Gaspari LA, Visini R, Iacobelli S:
Dynamic test with recombinant interferon-alpha-2b: effect on 90K and
other tumour-associated antigens in cancer patients without evidence of
disease. Br J Cancer 1993, 67(3):564–567.
17. Briggs NC, Natoli C, Tinari N, D’Egidio M, Goedert JJ, Iacobelli S: A 90-kDa
protein serum marker for the prediction of progression to AIDS in a
cohort of HIV-1+ homosexual men. AIDS Res Hum Retroviruses 1993,
9(9):811–816.
Lodermeyer et al. Retrovirology 2013, 10:111 Page 18 of 18
http://www.retrovirology.com/content/10/1/11118. Groschel B, Braner JJ, Funk M, Linde R, Doerr HW, Cinatl J Jr, Iacobelli S:
Elevated plasma levels of 90K (Mac-2 BP) immunostimulatory glycoprotein
in HIV-1-infected children. J Clin Immunol 2000, 20(2):117–122.
19. Iacobelli S, Natoli C, D’Egidio M, Tamburrini E, Antinori A, Ortona L:
Lipoprotein 90K in human immunodeficiency virus-infected patients: a
further serologic marker of progression. J Infect Dis 1991, 164(4):819.
20. Longo G, Natoli C, Rafanelli D, Tinari N, Morfini M, Rossi-Ferrini P, D’Ostilio N,
Iacobelli S: Prognostic value of a novel circulating serum 90K antigen in
HIV-infected haemophilia patients. Br J Haematol 1993, 85(1):207–209.
21. Natoli C, Dianzani F, Mazzotta F, Balocchini E, Pierotti P, Antonelli G, Iacobelli S: 90K
protein: a new predictor marker of disease progression in human
immunodeficiency virus infection. J Acquir Immune Defic Syndr 1993, 6(4):370–375.
22. Natoli C, Iacobelli S, Ghinelli F: Unusually high level of a tumor-associated
antigen in the serum of human immunodeficiency virus-seropositive
individuals. J Infect Dis 1991, 164(3):616–617.
23. Iacobelli S, Arno E, D’Orazio A, Coletti G: Detection of antigens recognized
by a novel monoclonal antibody in tissue and serum from patients with
breast cancer. Cancer Res 1986, 46(6):3005–3010.
24. Linsley PS, Horn D, Marquardt H, Brown JP, Hellstrom I, Hellstrom KE,
Ochs V, Tolentino E: Identification of a novel serum protein secreted by
lung carcinoma cells. Biochemistry 1986, 25(10):2978–2986.
25. Resnick D, Pearson A, Krieger M: The SRCR superfamily: a family
reminiscent of the Ig superfamily. Trends Biochem Sci 1994, 19(1):5–8.
26. Laferte S, Loh LC, Keeler V: Monoclonal antibodies specific for human
tumor-associated antigen 90K/Mac-2 binding protein: tools to examine
protein conformation and function. J Cell Biochem 2000, 77(4):540–559.
27. D’Ostilio N, Sabatino G, Natoli C, Ullrich A, Iacobelli S: 90K (Mac-2 BP) in
human milk. Clin Exp Immunol 1996, 104(3):543–546.
28. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A: Cloning and
characterization of a human Mac-2-binding protein, a new member of
the superfamily defined by the macrophage scavenger receptor
cysteine-rich domain. J Biol Chem 1993, 268(19):14245–14249.
29. Inohara H, Akahani S, Koths K, Raz A: Interactions between galectin-3 and Mac-2-
binding protein mediate cell-cell adhesion. Cancer Res 1996, 56(19):4530–4534.
30. Checkley MA, Luttge BG, Freed EO: HIV-1 envelope glycoprotein
biosynthesis, trafficking, and incorporation. J Mol Biol 2011, 410(4):582–608.
31. Crooks ET, Tong T, Osawa K, Binley JM: Enzyme digests eliminate
nonfunctional Env from HIV-1 particle surfaces, leaving native Env trimers
intact and viral infectivity unaffected. J Virol 2011, 85(12):5825–5839.
32. Nachmias D, Sklan EH, Ehrlich M, Bacharach E: Human immunodeficiency
virus type 1 envelope proteins traffic toward virion assembly sites via a
TBC1D20/Rab1-regulated pathway. Retrovirology 2012, 9:7.
33. Hellstern S, Sasaki T, Fauser C, Lustig A, Timpl R, Engel J: Functional studies
on recombinant domains of Mac-2-binding protein. J Biol Chem 2002,
277(18):15690–15696.
34. Trahey M, Weissman IL: Cyclophilin C-associated protein: a normal secreted
glycoprotein that down-modulates endotoxin and proinflammatory
responses in vivo. Proc Natl Acad Sci USA 1999, 96(6):3006–3011.
35. Muller SA, Sasaki T, Bork P, Wolpensinger B, Schulthess T, Timpl R, Engel A,
Engel J: Domain organization of Mac-2 binding protein and its
oligomerization to linear and ring-like structures. J Mol Biol 1999,
291(4):801–813.
36. Bieniasz PD, Cullen BR: Multiple blocks to human immunodeficiency virus
type 1 replication in rodent cells. J Virol 2000, 74(21):9868–9877.
37. Goujon C, Malim MH: Characterization of the alpha interferon-induced
postentry block to HIV-1 infection in primary human macrophages and T
cells. J Virol 2010, 84(18):9254–9266.
38. Hansen BD, Nara PL, Maheshwari RK, Sidhu GS, Bernbaum JG, Hoekzema D,
Meltzer MS, Gendelman HE: Loss of infectivity by progeny virus from
alpha interferon-treated human immunodeficiency virus type 1-infected
T cells is associated with defective assembly of envelope gp120. J Virol
1992, 66(12):7543–7548.
39. Dianzani F, Castilletti C, Gentile M, Gelderblom HR, Frezza F, Capobianchi
MR: Effects of IFN alpha on late stages of HIV-1 replication cycle.
Biochimie 1998, 80(8–9):745–754.
40. Binley JM, Sanders RW, Master A, Cayanan CS, Wiley CL, Schiffner L, Travis B,
Kuhmann S, Burton DR, Hu SL, et al: Enhancing the proteolytic maturation
of human immunodeficiency virus type 1 envelope glycoproteins. J Virol
2002, 76(6):2606–2616.
41. Wang P, Heitman J: The cyclophilins. Genome Biol 2005, 6(7):226.42. Pelliccia P, Galli L, de Martino M, Chiarelli F, Verrotti A, Sabatino G, Fornarini
B, Iacobelli S, Natoli C: Lack of mother-to-child HIV-1 transmission is
associated with elevated serum levels of 90 K immune modulatory
protein. Aids 2000, 14(4):F41–F45.
43. Fornarini B, Iacobelli S, Tinari N, Natoli C, De Martino M, Sabatino G: Human
milk 90K (Mac-2 BP): possible protective effects against acute respiratory
infections. Clin Exp Immunol 1999, 115(1):91–94.
44. Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, Hodohara K, Andoh A,
Fujiyama Y, Kawasaki T: Dendritic cell-specific intercellular adhesion
molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand,
Mac-2-binding protein, characteristically expressed on human colorectal
carcinomas. J Biol Chem 2011, 286(25):22403–22413.
45. Klein JS, Bjorkman PJ: Few and far between: how HIV may be evading
antibody avidity. PLoS Pathog 2010, 6(5):e1000908.
46. Goffinet C, Allespach I, Oberbremer L, Golden PL, Foster SA, Johns BA,
Weatherhead JG, Novick SJ, Chiswell KE, Garvey EP, et al: Pharmacovirological
impact of an integrase inhibitor on human immunodeficiency virus type 1
cDNA species in vivo. J Virol 2009, 83(15):7706–7717.
47. Schindler M, Rajan D, Banning C, Wimmer P, Koppensteiner H, Iwanski A,
Specht A, Sauter D, Dobner T, Kirchhoff F: Vpu serine 52 dependent
counteraction of tetherin is required for HIV-1 replication in macrophages,
but not in ex vivo human lymphoid tissue. Retrovirology 2010, 7:1.
48. Wildum S, Schindler M, Munch J, Kirchhoff F: Contribution of Vpu, Env, and
Nef to CD4 down-modulation and resistance of human
immunodeficiency virus type 1-infected T cells to superinfection. J Virol
2006, 80(16):8047–8059.
49. Habermann A, Krijnse-Locker J, Oberwinkler H, Eckhardt M, Homann S,
Andrew A, Strebel K, Krausslich HG: CD317/tetherin is enriched in the HIV-
1 envelope and downregulated from the plasma membrane upon virus
infection. J Virol 2010, 84(9):4646–4658.
doi:10.1186/1742-4690-10-111
Cite this article as: Lodermeyer et al.: 90K, an interferon-stimulated gene
product, reduces the infectivity of HIV-1. Retrovirology 2013 10:111.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
